Welcome to our dedicated page for SpyGlass Pharma SEC filings (Ticker: SGP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on SpyGlass Pharma's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into SpyGlass Pharma's regulatory disclosures and financial reporting.
SpyGlass Pharma’s major shareholder entity reported IPO-related conversions and a large share purchase. An entity associated with Edward T. Mathers, New Enterprise Associates 17, L.P. (NEA 17), a 10% owner, converted Series B, C-1, C-2 and D preferred stock into 1,619,240, 1,370,168, 1,370,168 and 737,962 shares of common stock, respectively, on February 9, 2026, immediately before the closing of the company’s initial public offering. NEA 17 also indirectly bought 937,500 additional common shares at $16 per share, bringing its indirectly held common stock position reported here to 6,035,038 shares. Mathers is a manager of NEA 17’s general partner and disclaims beneficial ownership of portions of NEA 17’s holdings in which he has no pecuniary interest.
SpyGlass Pharma director-affiliated entity increased its indirect stake through a conversion and open-market purchase. On 02/09/2026, 1,875,013 shares of Series D preferred stock automatically converted on a one-for-one basis into 1,875,013 shares of common stock immediately before SpyGlass Pharma’s initial public offering. On the same date, an affiliated entity purchased 312,500 additional common shares at $16 per share. Following these transactions, 2,187,513 common shares were reported as indirectly owned through Coöperatieve Gilde Healthcare VG VI U.A. and related Gilde Healthcare entities, with voting and dispositive power primarily held by Gilde Healthcare VG VI Management B.V. and certain individuals, who, along with the reporting person, disclaim beneficial ownership except for their pecuniary interests.
Khan Bilal Arshad, a director of SpyGlass Pharma, Inc., reported buying common stock in two open-market transactions on February 9, 2026 at $16 per share. He purchased 20,000 shares directly, bringing his direct holdings to 25,450 shares.
An affiliated entity, New World Medical, Inc., bought an additional 115,000 shares, increasing its indirect holdings reported for him to 251,427 shares. He is New World Medical’s Chief Executive Officer with voting and investment control but disclaims beneficial ownership of those shares except for his pecuniary interest.
Vensana Capital and its affiliates filed a Schedule 13D disclosing a 9.9% beneficial ownership stake in SpyGlass Pharma common stock. Vensana Capital I, L.P. directly holds 3,310,619 shares, with shared voting and dispositive power through its general partner and managing directors.
The stake reflects prior investments in multiple preferred stock rounds that converted into common stock at the company’s initial public offering, plus a purchase of 165,000 common shares at $16.00 per share on February 9, 2026. Director Kirk Nielsen also holds 1,522 option shares exercisable within 60 days.
SpyGlass Pharma director-affiliated entity reports IPO-related conversions and share purchase. Investment vehicle Vensana Capital I, L.P., associated with director Kirk G. Nielsen, converted multiple series of preferred stock into Common Stock on 02/09/2026 immediately before SpyGlass Pharma’s initial public offering.
The preferred shares converted to Common Stock at a one-for-5.7329 ratio without additional payment. Following these derivative conversions, Vensana Capital I, L.P. indirectly held 3,145,619 Common shares, then acquired an additional 165,000 Common shares in an open‑market purchase at $16 per share, bringing its indirect holdings to 3,310,619 Common shares.
SpyGlass Pharma insider entity Vensana Capital I, L.P., through its affiliated general partner, reported multiple transactions in connection with the company’s initial public offering. On February 9, 2026, its holdings of Series B, Series C‑1, Series C‑2 and Series D preferred stock automatically converted into common stock on a one‑for‑5.7329 basis immediately before the IPO, resulting in indirect ownership of 3,145,619 common shares. On the same date, the entity also purchased 165,000 common shares at $16 per share, bringing its total indirect common stock position to 3,310,619 shares, which are held by Vensana Capital I, L.P. The filing notes that Vensana Capital I GP, LLC and its managing directors, including board member Kirk Nielsen and Peter Justin Klein, may be deemed to share voting and investment power, but they disclaim beneficial ownership except to the extent of their pecuniary interests.
RA CAPITAL MANAGEMENT, L.P. reported acquisition or exercise transactions in a Form 4 filing for SGP. The filing lists transactions totaling 27,400 shares. Following the reported transactions, holdings were 27,400 shares.
Behbahani Ali reported acquisition or exercise transactions in a Form 4 filing for SGP. The filing lists transactions totaling 27,400 shares. Following the reported transactions, holdings were 27,400 shares.
Nielsen Kirk G. reported acquisition or exercise transactions in a Form 4 filing for SGP. The filing lists transactions totaling 27,400 shares. Following the reported transactions, holdings were 27,400 shares.
SpyGlass Pharma, Inc. director Zachary Scheiner was granted a stock option covering 27,400 shares of common stock at an exercise price of $16 per share on February 5, 2026. The option vests in equal monthly installments over 36 months, conditioned on his continuing service as an Outside Director.
According to the filing, Scheiner holds this option for the benefit of RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund III, L.P. Any net cash or stock received upon exercise must be turned over to RA Capital Management, L.P. to offset advisory fees, and Scheiner disclaims beneficial ownership of the option and underlying shares.